Deciphera Pharmaceuticals Inc

+0.60 (+1.82%)
Products, Regulatory

Deciphera Says Rebastinib With Paclitaxel Showed Preliminary Clinical Benefit In Platinum-Resistant Ovarian Cancer Patients

Published: 09/17/2020 11:22 GMT
Deciphera Pharmaceuticals Inc (DCPH) - Deciphera Presents Data From Rebastinib, Its Tie2 Inhibitor Program, at the European Society for Medical Oncology (esmo) Virtual Congress 2020.
Deciphera - Rebastinib With Paclitaxel Showed Preliminary Clinical Benefit, Favorable Tolerability in Platinum-resistant Ovarian Cancer Patients.
Deciphera - Rebastinib Combined With Carboplatin Was Well-tolerated in Patients With Metastatic Solid Tumors & Showed Initial Clinical Activity.
Deciphera Pharmaceuticals - at Rebastinib 50 Mg Bid Dose Level, Exposure of Rebastinib Was Generally Comparable to Previously Published Data.
Deciphera Pharmaceuticals - Part 2 Portion of Ongoing Phase 1/2 Study is Currently Enrolling.